The meticulous analysis of potential drugs serves as the cornerstone of pharmaceutical progress. This intricate evaluation entails a thorough examination of the molecular and biochemical attributes of candidate compounds. Researchers explore mechanisms of action, pharmacokinetics, and potential side effects, utilizing state-of-the-art technologies to anticipate efficacy and safety. Moreover, the analysis encompasses understanding how the drug interacts with biological pathways, ensuring a targeted therapeutic impact. This holistic approach takes into an account of potential drug-drug interactions, the influence of genetic variations on response, and the overall risk-benefit profile.
The incorporation of computational models and artificial intelligence introduces a layer of sophistication to drug analysis, enabling the anticipation of intricate interactions and potential outcomes. In essence, the scrutiny of potential drugs involves a dynamic fusion of scientific examination, technological advancement, and strategic planning all essential elements for navigating the intricate journey from discovery to pharmaceutical success.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico